Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NGM Biopharmaceuticals Inc.

www.ngmbio.com

Latest From NGM Biopharmaceuticals Inc.

Zydus Cadila First Off The Block In NASH After India Approval

Cadila Healthcare has received the first approval globally, in India, for a NASH therapy, after the national regulator cleared its candidate saroglitazar. The company also expects to begin Phase III trials in the US in the second quarter of fiscal 2021.

India Approvals

NGM’s Pan-FGF Receptor Approach In NASH Shows Benefits And Drawbacks

NGM’s Phase II data for FGF19 analog aldafermin shows ability to reduce liver fat and improve fibrosis, but also raises LDL-C. Company says it gets a broader effect this way and can manage the increased cholesterol.

Clinical Trials Business Strategies

89Bio’s NASH Hopes Hang On Demonstrating Best-In-Class FGF21 Profile

89Bio thinks its Phase II FGF21 analog could prove best-in-class in NASH due to a longer half-life than Bristol’s pegbelfermin, and avoid the LDL-increasing effects seen with NGM’s FGF19 analog.

Business Strategies Clinical Trials

NASH Companies Take The Stage At AASLD

NGM’s injectable might be best-suited as induction therapy for sicker NASH patients, Inventiva hopes its pan-PPAR agonist will outperform Genfit’s elafibranor, and Albireo thinks IBAT inhibition offers promise in NASH.

Research and Development Strategies Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Hepatic (Liver)
  • Metabolic Disorders
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • NGM Biopharmaceuticals Inc.
  • Senior Management
  • David Woodhouse, CEO & Interim CFO
    Jin-Long Chen, PhD, CSO
    Aetna Wun Trombley, PhD, Pres. & COO
    Hsiao D Lieu, MD, SVP, CMO
  • Contact Info
  • NGM Biopharmaceuticals Inc.
    Phone: (650) 243-5555
    333 Oyster Point Blvd.
    South San Francisco, CA 94080
    USA
UsernamePublicRestriction

Register